BioDelivery Sciences International is partnering with Evonik to develop a formulation of buprenorphine that can be subcutaneously injected and provide continuous therapy for 30 days. BDSI will pursue an approval for opioid dependence in about three years, but also aims to develop a product for chronic pain in patients requiring continuous opioid therapy.
Ken Drazan, the head of Johnson & Johnson's California Innovation Center, sat down with FierceMedicalDevices to muse on the company's interest in med tech.
Medtronic announced that its investigational aortic heart valve made using cow heart tissue has been implanted in its first U.S. patient, as the global, five-year Perigon trial of 650 patients gathers steam. It will be conducted at 40 sites in Europe, the U.S. and Canada.
Aileron Therapeutics has gone back to the well of investor cash and drawn up another $18 million in fresh support for its soon-to-launch, early-stage study of a p53 targeting cancer therapy.
Biopharma giants Amgen, Sanofi and Ono have joined a group of international academics to flesh out a promising but underexplored field of drug development, planning to share their discoveries with the public in hopes of galvanizing global R&D.
Novartis' pharma chief has hailed the company's forthcoming heart failure treatment as "the most exciting launch the company has ever had," and now the drugmaker's CEO has declared a "multi-blockbuster" in the making, joining a chorus of analysts who expect billions in annual sales from LCZ696.
Zoetis has embarked on a new mission to identify and quickly address diseases in livestock and companion animals by capitalizing on the latest advances in genetic sequencing and molecular biology. Towards that end, the company is teaming up with the Easter Bush Research Consortium--a group that includes several Scottish academic and scientific institutions--to form a new European research center headquartered in Edinburgh.
Late last year F-star spun out one of its early-stage drugs into a separate "asset-centric" company dubbed F-star Alpha. A group of venture players including Atlas and SR One chipped in $12 million to fund the clinical plans for the HER2-targeting antibody fragment FS102. And now Bristol-Myers Squibb has come along and seized the prize, nabbing a buyout option on the spinout as well as worldwide rights for an upfront and near-term milestone payment of $50 million in a deal that is worth up to $475 million.
Watertown, MA's Syros Pharmaceuticals has banked a massive $53 million Series B to support its innovative approach to treating cancer, targeting the genetic switches responsible for tumor growth.
The Association of Clinical Research Organizations, which represents the world's largest CROs, is putting together a sort of contractors' council to weigh in on the efforts of TransCelerate BioPharma, a nonprofit group run by the biggest names in drug development.